# A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

> **NCT05731128** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 68 (actual)

## Conditions studied

- Colitis Ulcerative

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05731128
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-12
- **Primary completion:** 2026-05-15
- **Final completion:** 2027-02-19
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05731128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05731128, "A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05731128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*